Hinton, William
Feher, Michael D.
Munro, Neil
Joy, Mark
de Lusignan, Simon http://orcid.org/0000-0002-8553-2641
Funding for this research was provided by:
AstraZeneca UK Limited
Article History
Received: 15 March 2021
Accepted: 7 June 2021
First Online: 28 June 2021
Declarations
:
: The study was checked against the Health Research Authority (HRA) Medical Research Council (MRC) tool for identifying research, and was identified as a clinical audit. The study requirements were also checked against the Research Integrity and Governance Office’s (at the University of Surrey) Self-Assessment for Governance and Ethics tool, which confirmed that a formal ethics review was not required for this work. The Oxford-RCGP RSC Study Approval Committee approved this study for access to key variables within the database. Data were pseudonymised at the time of extraction and therefore, personal data were not identifiable to the researchers. Informed consent was not required for this study. As per the UK National Data Guardian consent/opt-out model [CitationRef removed], data were not processed for patients with flags in their records to indicate they opted out of data sharing.
: Informed consent was not required, which is in compliance with the UK National Data Guardian consent/opt-out model.
: William Hinton has had part of his academic salary funded from grant awards with Eli Lilly and Company, Novo Nordisk Limited, and AstraZeneca UK Ltd. Michael Feher receives financial support for research, speaker meetings and consultancy from AMGEN, MSD, Merck, AstraZeneca, Pfizer, Novo Nordisk Ltd, Eli Lilly and Co., and Sanofi-Aventis. Neil Munro has received financial support for research, speaker meetings and consultancy from MSD, Merck, BMS, AstraZeneca, Pfizer, Novo Nordisk Ltd, Eli Lilly and Co., and Sanofi-Aventis. Mark Joy has no competing interests. Simon de Lusignan holds or had recently held grants from Eli Lilly and Company, AstraZeneca, and Novo Nordisk Ltd. through his university for investigator-led research in diabetes.